1-9 of 9
Christophe Le Tourneau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons

Open Access
Marc Michel, Maryam Heidary, Anissa Mechri, Kévin Da Silva, Marine Gorse, Victoria Dixon, Klaus von Grafenstein, Charline Bianchi, Caroline Hego, Aurore Rampanou, Constance Lamy, Maud Kamal, Christophe Le Tourneau, Mathieu Séné, Ivan Bièche, Cécile Reyes, David Gentien, Marc-Henri Stern, Olivier Lantz, Luc Cabel, Jean-Yves Pierga, François-Clément Bidard, Chloé-Agathe Azencott, Charlotte Proudhon
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (7): 1275–1291.
https://doi.org/10.1158/1078-0432.CCR-24-2669
Published: 01 April 2025
View articletitled, Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Open the PDF for Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons in another window
Includes: Supplementary data
Journal Articles

Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689

Free
Arkadiy Klochikhin, Robert I. Haddad, Amichay Meirovitz, Sufia Safina, Irene Brana, Christophe Le Tourneau, Ravindra Uppaluri, Nancy Y. Lee, Ezra E. W. Cohen, Rebecca Chernock, William Westra, Hong Liu, Burak Gumuscu, Kimberly Benjamin, Douglas Adkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-002.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-002
Published: 15 September 2023
View articletitled, Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689
Journal Articles

Abstract PR05: Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: From bench to bedside

Free
Colette J. Shen, Christophe Le Tourneau, Zoltán Takacsi-Nagy, Xavier Liem, Jessica Frakes, Jiaxin Niu, Jared Weiss, Jimmy Caudell, Yun Hu, James W. Welsh, Sebastien Paris, Anais Debard, Patricia Said, Pavel Tyan, Tanguy Y. Seiwert, Zsuzsanna Papai, Omar I. Vivar, Leonard A. Farber, Ari Rosenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PR05.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PR05
Published: 15 September 2023
View articletitled, Abstract PR05: Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: From bench to bedside
Journal Articles

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Open Access
Emmanuelle Jeannot, Aurélien Latouche, Claire Bonneau, Marie-Ange Calméjane, Corine Beaufort, Kirsten Ruigrok-Ritstier, Guillaume Bataillon, Linda Larbi Chérif, Célia Dupain, Charlotte Lecerf, Marina Popovic, Anne de la Rochefordière, Fabrice Lecuru, Virginie Fourchotte, Ekaterina S. Jordanova, Heiko von der Leyen, Carine Tran-Perennou, Marie-Emmanuelle Legrier, Sylvain Dureau, Laurence Raizonville, Diana Bello Roufai, Christophe Le Tourneau, Ivan Bièche, Roman Rouzier, Els M.J.J. Berns, Maud Kamal, Suzy Scholl
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5869–5877.
https://doi.org/10.1158/1078-0432.CCR-21-0625
Published: 01 November 2021
View articletitled, Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
Open the PDF for Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Available to Purchase
Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, Valerie Cristina, Edith Borcoman, Eric Deutsch, Rastislav Bahleda, Valentin Calugaru, Anouchka Modesto, Elisabeth Rouits, Kathrin Gollmer, Gregoire Vuagniaux, Philippa Crompton, Claudio Zanna, Sergio Szyldergemajn, Jean-Pierre Delord, Jean Bourhis
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6429–6436.
https://doi.org/10.1158/1078-0432.CCR-20-0425
Published: 15 December 2020
View articletitled, Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Free
Daniel D. Von Hoff, Drew W. Rasco, Elisabeth I. Heath, Pamela N. Munster, Jan H.M. Schellens, Nicolas Isambert, Christophe Le Tourneau, Bert O'Neil, Ron H.J. Mathijssen, Jose A. Lopez-Martin, W. Jeff Edenfield, Miguel Martin, Patricia M. LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4072–4080.
https://doi.org/10.1158/1078-0432.CCR-17-3716
Published: 04 September 2018
View articletitled, Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Open the PDF for Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Free
Hope S. Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina A. Piha-Paul, Philippe L. Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-17-3452
Published: 14 June 2018
View articletitled, Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Open the PDF for Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Free
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Valentina Boni, Alvaro Taus, Joan Albanell, Marie-Paule Sablin, Marie Alt, Ratislav Bahleda, Andrea Varga, Christophe Boetsch, Izolda Franjkovic, Florian Heil, Angelika Lahr, Katharina Lechner, Anthony Morel, Tapan Nayak, Simona Rossomanno, Kevin Smart, Kay Stubenrauch, Oliver Krieter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1536–1545.
https://doi.org/10.1158/1078-0432.CCR-17-1588
Published: 02 April 2018
View articletitled, First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Free
Fabian Birzele, Edgar Voss, Adam Nopora, Konrad Honold, Florian Heil, Sabine Lohmann, Henk Verheul, Christophe Le Tourneau, Jean-Pierre Delord, Carla van Herpen, Devalingam Mahalingam, Andrew L. Coveler, Valerie Meresse, Stefan Weigand, Valeria Runza, Michael Cannarile
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (12): 2753–2762.
https://doi.org/10.1158/1078-0432.CCR-14-2141
Published: 14 June 2015
View articletitled, CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Open the PDF for CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients in another window
Includes: Supplementary data